1. Kaempferol Incorporated Bovine Serum Albumin Fibrous Films for Ocular Drug Delivery
- Author
-
Chuanlong Guo, Xueju Qi, Yalu Liu, Chuanjin Yin, and Xiaochen Wu
- Subjects
Drug ,Male ,Antioxidant ,genetic structures ,Polymers and Plastics ,media_common.quotation_subject ,medicine.medical_treatment ,Bioengineering ,Cell Line ,Biomaterials ,Neovascularization ,Cornea ,chemistry.chemical_compound ,Mice ,In vivo ,Corneal Injury ,Materials Chemistry ,medicine ,Animals ,Humans ,Bovine serum albumin ,media_common ,Mice, Inbred BALB C ,biology ,Membranes, Artificial ,Serum Albumin, Bovine ,Contact Lenses, Hydrophilic ,eye diseases ,chemistry ,Delayed-Action Preparations ,Drug delivery ,Biophysics ,biology.protein ,Cattle ,sense organs ,medicine.symptom ,Kaempferol ,Biotechnology - Abstract
The possibility of using drug loaded bovine serum albumin (BSA) porous films as therapeutic contact lenses is investigated. Kaempferol (KAE), a hydrophobic antioxidant and anti-inflammatory agent, is incorporated into BSA porous films to form BSA/KAE films. The BSA/KAE films are transparent in the visible wavelength range of the human eye, possessing high water content and good cytocompatibility. A prolonged and sustained drug release is observed, and the in vivo efficacy of BSA/KAE films is better than the individual KAE. BSA/KAE films promoted the corneal re-epithelialization, inhibited neovascularization, and reduced the inflammation of an alkali burn induced corneal injury model. The study demonstrates the promising potential of BSA/KAE films as therapeutic contact lenses for the treatment of corneal injury, builds an available ocular drug delivery platform for ocular diseases.
- Published
- 2021